Literature DB >> 26862110

Clinical and laboratory variability in a cohort of patients diagnosed with type 1 VWD in the United States.

Veronica H Flood1, Pamela A Christopherson2, Joan Cox Gill1, Kenneth D Friedman3, Sandra L Haberichter1, Daniel B Bellissimo2, Rupa A Udani2, Mahua Dasgupta4, Raymond G Hoffmann4, Margaret V Ragni5, Amy D Shapiro6, Jeanne M Lusher7, Steven R Lentz8, Thomas C Abshire9, Cindy Leissinger10, W Keith Hoots11, Marilyn J Manco-Johnson12, Ralph A Gruppo13, Lisa N Boggio14, Kate T Montgomery15, Anne C Goodeve16, Paula D James17, David Lillicrap17, Ian R Peake16, Robert R Montgomery1.   

Abstract

von Willebrand disease (VWD) is the most common inherited bleeding disorder, and type 1 VWD is the most common VWD variant. Despite its frequency, diagnosis of type 1 VWD remains the subject of debate. In order to study the spectrum of type 1 VWD in the United States, the Zimmerman Program enrolled 482 subjects with a previous diagnosis of type 1 VWD without stringent laboratory diagnostic criteria. von Willebrand factor (VWF) laboratory testing and full-length VWF gene sequencing was performed for all index cases and healthy control subjects in a central laboratory. Bleeding phenotype was characterized using the International Society on Thrombosis and Haemostasis bleeding assessment tool. At study entry, 64% of subjects had VWF antigen (VWF:Ag) or VWF ristocetin cofactor activity below the lower limit of normal, whereas 36% had normal VWF levels. VWF sequence variations were most frequent in subjects with VWF:Ag <30 IU/dL (82%), whereas subjects with type 1 VWD and VWF:Ag ≥30 IU/dL had an intermediate frequency of variants (44%). Subjects whose VWF testing was normal at study entry had a similar rate of sequence variations as the healthy controls (14%). All subjects with severe type 1 VWD and VWF:Ag ≤5 IU/dL had an abnormal bleeding score (BS), but otherwise BS did not correlate with VWF:Ag. Subjects with a historical diagnosis of type 1 VWD had similar rates of abnormal BS compared with subjects with low VWF levels at study entry. Type 1 VWD in the United States is highly variable, and bleeding symptoms are frequent in this population.
© 2016 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26862110      PMCID: PMC4874228          DOI: 10.1182/blood-2015-10-673681

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  44 in total

1.  Slippery criteria for von Willebrand disease type 1.

Authors:  J E Sadler
Journal:  J Thromb Haemost       Date:  2004-10       Impact factor: 5.824

2.  von Willebrand disease and aging: an evolving phenotype.

Authors:  Y V Sanders; M A Giezenaar; B A P Laros-van Gorkom; K Meijer; J G van der Bom; M H Cnossen; M R Nijziel; P F Ypma; K Fijnvandraat; J Eikenboom; E P Mauser-Bunschoten; F W G Leebeek
Journal:  J Thromb Haemost       Date:  2014-07       Impact factor: 5.824

3.  ISTH/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders.

Authors:  F Rodeghiero; A Tosetto; T Abshire; D M Arnold; B Coller; P James; C Neunert; D Lillicrap
Journal:  J Thromb Haemost       Date:  2010-09       Impact factor: 5.824

4.  Intersection of mechanisms of type 2A VWD through defects in VWF multimerization, secretion, ADAMTS-13 susceptibility, and regulated storage.

Authors:  Paula M Jacobi; Joan Cox Gill; Veronica H Flood; David A Jakab; Kenneth D Friedman; Sandra L Haberichter
Journal:  Blood       Date:  2012-03-19       Impact factor: 22.113

5.  Quantitative impact of using different criteria for the laboratory diagnosis of type 1 von Willebrand disease.

Authors:  T Quiroga; M Goycoolea; S Belmont; O Panes; E Aranda; P Zúñiga; J Pereira; D Mezzano
Journal:  J Thromb Haemost       Date:  2014-06-27       Impact factor: 5.824

6.  Mutation distribution in the von Willebrand factor gene related to the different von Willebrand disease (VWD) types in a cohort of VWD patients.

Authors:  Hamideh Yadegari; Julia Driesen; Anna Pavlova; Arijit Biswas; Hans-Jörg Hertfelder; Johannes Oldenburg
Journal:  Thromb Haemost       Date:  2012-08-07       Impact factor: 5.249

7.  CLEC4M and STXBP5 gene variations contribute to von Willebrand factor level variation in von Willebrand disease.

Authors:  Y V Sanders; J G van der Bom; A Isaacs; M H Cnossen; M P M de Maat; B A P Laros-van Gorkom; K Fijnvandraat; K Meijer; C M van Duijn; E P Mauser-Bunschoten; J Eikenboom; F W G Leebeek
Journal:  J Thromb Haemost       Date:  2015-05-09       Impact factor: 5.824

8.  Laboratory tests for measurement of von Willebrand factor show poor agreement among different centers: results from the United Kingdom National External Quality Assessment Scheme for Blood Coagulation.

Authors:  Steve Kitchen; Ion Jennings; Tim A L Woods; Dianne P Kitchen; Isobel D Walker; Francis E Preston
Journal:  Semin Thromb Hemost       Date:  2006-07       Impact factor: 4.180

9.  A sensitive ELISA for von Willebrand factor (vWf:Ag).

Authors:  J Ingerslev
Journal:  Scand J Clin Lab Invest       Date:  1987-04       Impact factor: 1.713

10.  Prevalence of von Willebrand disease in children: a multiethnic study.

Authors:  E J Werner; E H Broxson; E L Tucker; D S Giroux; J Shults; T C Abshire
Journal:  J Pediatr       Date:  1993-12       Impact factor: 4.406

View more
  36 in total

Review 1.  Advances in the diagnosis and treatment of Von Willebrand disease.

Authors:  Ruchika Sharma; Veronica H Flood
Journal:  Blood       Date:  2017-11-30       Impact factor: 22.113

2.  The role of genetics in the pathogenesis and diagnosis of type 1 Von Willebrand disease.

Authors:  Veronica H Flood; Jessica Garcia; Sandra L Haberichter
Journal:  Curr Opin Hematol       Date:  2019-09       Impact factor: 3.284

3.  Defective collagen binding and increased bleeding in a murine model of von Willebrand disease affecting collagen IV binding.

Authors:  T L Slobodianuk; C Kochelek; J Foeckler; S Kalloway; H Weiler; V H Flood
Journal:  J Thromb Haemost       Date:  2018-12-18       Impact factor: 5.824

4.  Von Willebrand disease in the United States: perspective from the Zimmerman program.

Authors:  Veronica H Flood; Thomas C Abshire; Pamela A Christopherson; Kenneth D Friedman; Joan Cox Gill; Robert R Montgomery; Sandra L Haberichter
Journal:  Ann Blood       Date:  2018-01-26

5.  Novel insights into the clinical phenotype and pathophysiology underlying low VWF levels.

Authors:  Michelle Lavin; Sonia Aguila; Sonja Schneppenheim; Niall Dalton; Kenneth L Jones; Jamie M O'Sullivan; Niamh M O'Connell; Kevin Ryan; Barry White; Mary Byrne; Marie Rafferty; Mairead M Doyle; Margaret Nolan; Roger J S Preston; Ulrich Budde; Paula James; Jorge Di Paola; James S O'Donnell
Journal:  Blood       Date:  2017-09-15       Impact factor: 22.113

Review 6.  Flow chamber and microfluidic approaches for measuring thrombus formation in genetic bleeding disorders.

Authors:  Rogier M Schoeman; Marcus Lehmann; Keith B Neeves
Journal:  Platelets       Date:  2017-05-22       Impact factor: 3.862

Review 7.  Advances in the diagnosis and treatment of Von Willebrand disease.

Authors:  Ruchika Sharma; Veronica H Flood
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

8.  The Association of Aging With Von Willebrand Factor Levels and Bleeding Risk in Type 1 Von Willebrand Disease.

Authors:  Craig D Seaman; Margaret V Ragni
Journal:  Clin Appl Thromb Hemost       Date:  2017-09-06       Impact factor: 2.389

9.  The endothelial cell receptor stabilin-2 regulates VWF-FVIII complex half-life and immunogenicity.

Authors:  Laura L Swystun; Jesse D Lai; Colleen Notley; Ilinca Georgescu; A Simonne Paine; Jeff Mewburn; Kate Nesbitt; Kai Schledzewski; Cyrill Géraud; Julia Kzhyshkowska; Sergij Goerdt; Wilma Hopman; Robert R Montgomery; Paula D James; David Lillicrap
Journal:  J Clin Invest       Date:  2018-08-20       Impact factor: 14.808

10.  Evaluation of a microfluidic flow assay to screen for von Willebrand disease and low von Willebrand factor levels.

Authors:  M Lehmann; K Ashworth; M Manco-Johnson; J Di Paola; K B Neeves; C J Ng
Journal:  J Thromb Haemost       Date:  2017-11-23       Impact factor: 5.824

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.